MURRAY, Utah, July 12, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it expects to release financial results for the three months ended June 30, 2023, before market open on Wednesday, August 2, 2023.
R1’s management team will host a conference call on August 2 at 8:00 a.m. ET to discuss the results and business outlook. To participate, please dial 888-330-2022 (646-960-0690 outside the U.S. and Canada) using conference code number 5681952. A live webcast and replay of the call will be available at the Investor Relations section of the Company’s website at www.r1rcm.com.
About R1 RCM
R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more, visit: www.r1rcm.com.
Contact:
R1 RCM Inc.
Investor Relations:
Atif Rahim
312.324.5476
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations:
Allison + Partners
Amanda Critelli
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$12.48 |
| Daily Change: | -0.03 -0.24 |
| Daily Volume: | 103,348 |
| Market Cap: | US$5.250B |
May 08, 2024 February 27, 2024 February 16, 2024 January 08, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORE
